NAMS Stock Analysis: Buy, Sell, or Hold?
NAMS - NewAmsterdam Pharma Company N.V. Ordinary Shares
$35.47
-1.52 (-4.11%)
▼
5d:
+4.66%
30d:
+12.53%
90d:
+4.6%
BUY
MODERATE Confidence
Analysis Updated: Jul 7, 2026 12:00 AM ET
Earnings: Aug 05, 2026
27d
Smart Money Distribution
None View Scanner →
Strength: 6.4/10
Get Alerted When NAMS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called NAMS this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NAMS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: NAMS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: NAMS is currently trading at $35.47, which is considered slightly high relative to its 30-day fair value range of $30.25 to $34.22.
Technical Outlook: Technically, NAMS is showing sideways momentum. The price is approaching resistance at $36.34. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. Short-term momentum is weak, with the stock down 4.1% recently.
Market Sentiment: NAMS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $49.68 (+34.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NAMS is showing sideways momentum. The price is approaching resistance at $36.34. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. Short-term momentum is weak, with the stock down 4.1% recently.
Market Sentiment: NAMS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $49.68 (+34.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$30.25 -
$34.22
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
73.7%
All Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.1%)
- BULLISH: Trading 34.3% below Wall St target ($49.68)
Trading Range Analysis
30-Day Trading Range
$30.25 -
$34.22
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$30.31
Resistance Level
$36.34
Current Trend
Sideways
Technical data as of
Jul 7, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-28.04
Wall Street Target
$49.68
(+34.3%)
Revenue Growth (YoY)
2.1%
Share & Embed Analysis
Last updated: July 08, 2026 12:52 PM ET
Data refreshes hourly during market hours. Next update: 1:52 PM
Data refreshes hourly during market hours. Next update: 1:52 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NAMS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
14
Sells
Net
INSIDERS SELLING
Recent Transactions
Louis G Lange
SELL
44619 shares
2026-03-11
Johannes Jacob Piete Kas…
SELL
101409 shares
2026-03-09
Johannes Jacob Piete Kas…
SELL
94124 shares
2026-03-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 60 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 63 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 66 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 57 HOLD |
Advanced NAMS Option Strategies
Professional options setups generated by AI based on today's NAMS price and gamma walls.
